SCHEMBL4978591

SCHEMBL4978591

Cc1ccc(Nc2nccc(N(C)c3cccc4c3nc(NC(=O)Cc3ccc(Cl)c(Cl)c3)n4C)n2)cc1S(N)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.45
CYP3A4 P08684 5/20 0.45
CYP2D6 P10635 5/20 0.45
CYP2C9 P11712 5/20 0.45
CYP2C19 P33261 5/20 0.45
AURKA O14965 3/20 0.45
ABCB11 O95342 2/20 0.45
RIPK1 Q13546 2/20 0.45
RIPK3 Q9Y572 2/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
BMPR1B O00238 1/20 0.45
PLK4 O00444 1/20 0.45
GAK O14976 1/20 0.45
EPHB6 O15197 1/20 0.45
ABCC4 O15439 1/20 0.45
RIPK2 O43353 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978600 0.86 LMNA (0.46) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5223137 0.86 KDR (0.56) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4977078 0.85 KDR (0.45) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4978457 0.80 KDR (0.47) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4979215 0.79 ALK (0.38) KDRMAP4K4ABL1LCKFYN
SCHEMBL4978443 0.78 KDR (0.39) KDRALDH1A1LMNAMAPTHTT
SCHEMBL5225318 0.78 SMN1; SMN2 (0.43) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4976580 0.77 MEN1 (0.38) KDRALDH1A1LMNAMAPTHTT
SCHEMBL5225600 0.74 KDR (0.62) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5224590 0.74 KDR (0.54) KDRCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US claimed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US claimed
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors TIE1, TEK, KDR KDR 3/4885CYP3A4 3874/4885CYP2D6 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.